플루아드®는 MF59® 면역증강제를 포함한 인플루엔자 백신으로,
만 65세 이상 고령층에게 접종할 수 있습니다.1

MF59® 면역증강제 첨가

고령층의 면역 반응 감소를 고려한
면역증강 인플루엔자 백신입니다.1-3

icon_vaccine

만 65세 이상 접종 가능

만 65세 이상에서 인플루엔자 질환
예방을 위해 접종할 수 있습니다.1

icon_65

주요 국가 허가 및 접종 권고

미국 FDA, 유럽 EMA, 영국 MHRA 등
주요 국가의 허가를 받은 MF59®
면역증강 인플루엔자 백신으로,4-7
미국, 영국, 호주 및 우리나라에서
만 65세 이상 성인에게 접종이
권고되고 있습니다.8-11

icon_flag_01 icon_flag_03 icon_flag_04 icon_flag_05

실제 진료환경 연구 축적

여러 연구에서 MF59® 면역증강
인플루엔자 백신의 인플루엔자 감염 및
관련 합병증 예방 효과가
보고되었습니다.12-19

icon_graph
icon_contact

올해 독감 예방접종 전,
플루아드®에 대해 의료진과 상담해 보세요.

올해 독감 예방접종 전,
플루아드®에 대해 의료진과 상담해 보세요.

icon_injection
MF59® 면역증강 인플루엔자 백신 플루아드®는
강한 면역 반응을 유도하여 고령층에게 적합한 백신입니다.2,4-5
MF59® 면역증강
인플루엔자 백신 플루아드®는
강한 면역 반응을 유도하여
고령층에게 적합한 백신입니다.2,4-5
REFERENCES icon_arrow
  1. 식품의약품안전처 의약품통합정보시스템 의약품제품정보 상세보기(플루아드프리필드시린지주).
  2. Monto AS, et al. Influenza control in the 21st century: Optimizing protection of older adults. Vaccine. 2009;27(37):5043-5053.
  3. Frey SE, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027-5034.
  4. Food and Drug Administration. Supplement approval letter including an accelerated approval: Fluad.
  5. European Medicines Agency. Fluad European Public Assessment Report.
  6. UK Health Security Agency. Flu vaccines for the 2025 to 2026 season. GOV.UK. Available at: https://www.gov.uk/government/publications/flu-vaccines-for-the-current-season/flu-vaccines-for-the-2023-to-2024-season Last accessed 04 Aug 2026.
  7. MHRA. Marketing authorisations granted 1 July 2024 to 14 July 2024. PLGB 47991/0014; grant date July 2, 2024. Last accessed 04 Aug 2026.
  8. Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025–26 Influenza Season. MMWR Morb Mortal Wkly Rep. 2025;74(32):500-507.
  9. JCVI statement on influenza vaccines for 2026 to 2027 - GOV.UK Updated 12 November 2025. Last accessed 11 June 2026.
  10. Adults aged ≥65 years are recommended to receive influenza vaccine every year. https://immunisationhandbook.health.gov.au/recommendations/adults-aged-65-years-are-recommended-to-receive-influenza-vaccine-every-year Last updated 13 March 2026, Last reviewed 13 March 2026.
  11. 대한감염학회. 성인예방접종권고안. 인플루엔자백신.
  12. Izurieta HS, et al. Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018–2019. J Infect Dis. 2020;222:278-287.
  13. Boikos C, et al. Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons. Clin Infect Dis. 2021;73(5):816-823.
  14. Pelton SI, et al. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season. Vaccines (Basel). 2020;8(3):E446.
  15. McConeghy KW, et al. Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US Nursing Homes. Clin Infect Dis. 2021;73(11):e4237-e4243.
  16. Cocchio S, et al. Preventing the Risk of Hospitalization for Respiratory Complications of Influenza among the Elderly: is There a Better Influenza Vaccination Strategy? A Retrospective Population Study. Vaccines (Basel). 2020;8(3):344.
  17. Van Buynder PG, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013;31(51):6122-6128.
  18. Mannino S, et al. Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy. Am J Epidemiol. 2012;176(6):527-533.
  19. Lapi F, et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines. 2019;18(6):663-670.
광고심의필 2026-1814-102100 KOR-ATIV-26-0035
icon_fluad

플루아드®
병원 찾기